Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses

Simple item page
dc.citation.articleNumber100128
dc.citation.journalTitleOne Health
dc.citation.volumeNumber9
dc.contributor.authorAmirian, E. Susan
dc.contributor.authorLevy, Julie K.
dc.contributor.orgTexas Policy Lab
dc.contributor.publisherElsevier
dc.date.accessioned2020-04-24T15:49:15Z
dc.date.available2020-04-24T15:49:15Z
dc.date.issued2020
dc.description.abstractRecent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on in vitro and in vivo studies (including some on a chemically related compound, GS-441524™), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community.
dc.identifier.citationAmirian, E. Susan and Levy, Julie K.. "Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses." <i>One Health,</i> 9, (2020) https://doi.org/10.1016/j.onehlt.2020.100128.
dc.identifier.doihttps://doi.org/10.1016/j.onehlt.2020.100128
dc.identifier.urihttps://hdl.handle.net/1911/108372
dc.language.isoeng
dc.rightsThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.keywordRemdesivir
dc.subject.keywordGS-5734
dc.subject.keywordCoronavirus
dc.subject.keywordCOVID-19
dc.subject.keywordSARS-CoV-2
dc.subject.keywordCompassionate use
dc.titleCurrent knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpublisher version
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Remdesivir_Review_Amirian.pdf
Size:
345 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Rice Coronavirus Research